Patents Assigned to Wyeth
  • PTH responsive gene
    Patent number: 7258999
    Abstract: This invention relates to a novel PTH gene. The invention further relates to methods of screening, diagnosis and development of therapies for bone related disorders.
    Type: Grant
    Filed: November 10, 2003
    Date of Patent: August 21, 2007
    Assignee: Wyeth
    Inventors: John Allen Robinson, Vedrana Stojanovic-Susulic, Philip Babij, Richard John Murrills
  • Aryl, aryloxy, and aklyloxy substituted 1-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
    Patent number: 7259182
    Abstract: Compounds of formula I are provided: wherein: R1, R2, and R3, are as defined herein, as well as pharmaceutical composition and methods using the compounds as inhibitors of plasminogen activator inhibitor (PAI-1) and as therapeutic composition for treating conditions resulting from fibrinolytic disorders, such as deep vein thrombosis, coronary heart disease and pulmonary fibrosis.
    Type: Grant
    Filed: December 9, 2003
    Date of Patent: August 21, 2007
    Assignee: Wyeth
    Inventors: Lee Dalton Jennings, Hassan Mahmoud Elokdah, Geraldine Ruth McFarlane
  • Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 7259165
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: February 13, 2004
    Date of Patent: August 21, 2007
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Yinfa Yan
  • Advanced route for the synthesis of cPLA2 inhibitors
    Patent number: 7259277
    Abstract: A process for making a compound of formula (I) in which process the compound HC?C—(CH2)n—NH2 is reacted with the compound R1—SO2Cl to produce an intermediate compound, which intermediate compound is then reacted with the compound of formula to produce the compound of formula (I), and compounds produced by the process of this invention. The terms R1, R2, R3, R4 and n have the definitions set forth in the specification.
    Type: Grant
    Filed: March 8, 2005
    Date of Patent: August 21, 2007
    Assignee: Wyeth
    Inventors: Yanzhong Wu, Panolil Raveendrath
  • Circovirus sequences associated with piglet weight loss disease (PWD)
    Patent number: 7258865
    Abstract: The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection is further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
    Type: Grant
    Filed: December 23, 2005
    Date of Patent: August 21, 2007
    Assignee: Wyeth
    Inventors: Andre Jestin, Emmanuel Albina, Pierre Le Cann, Philippe Blanchard, Evelyne Hutet, Claire Arnauld, Catherine Truong, Dominique Mahe, Roland Cariolet, Francois Madec
  • Recombiant lubricin molecules and uses thereof
    Publication number: 20070191268
    Abstract: Recombinant lubricin molecules and uses thereof Novel recombinant lubricin molecules and their uses as lubricants anti-adhesive agents and/or intra-articular supplements for, e.g., synvial joints, meniscus, tendon, peritoneum, pericardium and pleura are provided.
    Type: Application
    Filed: August 13, 2004
    Publication date: August 16, 2007
    Applicant: WYETH
    Inventors: Carl Flannery, Christopher Corcoran, Bethany Freeman, Lisa Collins-Racie
  • Passive targeting of cytotoxic agents
    Publication number: 20070190060
    Abstract: The present invention provides methods of treating cancer cells comprising administering to a patient in need thereof a therapeutically effective amount of a non-specific antibody conjugated to a cytotoxin, wherein the cancer cells do not express an antigen to which the non-specific antibody binds. In one embodiment, the non-specific antibody is an anti-CD33 antibody (e.g., hp67.6), an anti-CD22 antibody (e.g., g5/44), or an anti-CD20 antibody (e.g., rituximab). In another embodiment, the non-specific antibody does not bind a human antigen. The cancer cells treated can be, e.g., gastric, colon, non-small cell lung (NSCLC), breast, epidermoid, or prostate carcinoma cells. In one embodiment, the cytotoxin is calicheamicin. Calicheamicin can be conjugated to the non-specific antibody using a 4-(4?-acetylphenoxy)butanoic acid (AcBut) or (3-Acetylphenyl)acetic acid (AcPAc) linker.
    Type: Application
    Filed: March 15, 2005
    Publication date: August 16, 2007
    Applicant: Wyeth
    Inventors: Erwin Boghaert, Kiran Khandke, Nitin Damle
  • Novel binding site for retigabine on KCNQ5
    Publication number: 20070190554
    Abstract: Disclosed herein are nucleic acid and polypeptide sequences of mutated KCNQ5 potassium channels which lack responsiveness to the potassium channel activator retigabine. Also disclosed herein are methods and kits related to the use of the aforementioned mutated KCNQ5 potassium channels.
    Type: Application
    Filed: January 17, 2007
    Publication date: August 16, 2007
    Applicant: Wyeth
    Inventors: Kun Liu, Qiang Wang, Thomas Argentieri
  • Novel rat voltage-gated potassium channel
    Publication number: 20070190553
    Abstract: Disclosed herein are nucleic acid and polypeptide sequences of a novel rat voltage-gated potassium channel, KCNQ5. Also disclosed herein are methods related to the use of the aforementioned potassium channel.
    Type: Application
    Filed: January 17, 2007
    Publication date: August 16, 2007
    Applicant: Wyeth
    Inventors: Qiang Wang, Thomas Argentieri
  • 2-Amino-5-piperidinylimidazolone compounds and use thereof for beta-secretase modulation
    Publication number: 20070191431
    Abstract: The present invention provides a 2-amino-5-piperidinylimidazolone compound of formula I The present invention also provides methods and compositions for the inhibition of ?-secretase (BACE) and the treatment of ?-amyloid deposits and neurofibrillary tangles.
    Type: Application
    Filed: December 18, 2006
    Publication date: August 16, 2007
    Applicant: Wyeth
    Inventors: Ping Zhou, Ronald Bernotas, Yanfang Li, Pawel Nowak, Derek Cole, Eric Manas, Yi Fan, Yinfa Yan
  • Humanized antibodies that recognize beta amyloid peptide
    Patent number: 7256273
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include humanized antibodies.
    Type: Grant
    Filed: March 12, 2003
    Date of Patent: August 14, 2007
    Assignees: Elan Pharma International Limited, Wyeth
    Inventors: Guriq Basi, Jose Saldanha
  • Pyrimidoindolones and methods for using same
    Patent number: 7256198
    Abstract: Novel pyrimidoindolone compounds are disclosed. Methods of using the pyrimidoindolone compounds and compositions containing the compounds in the treatment and/or prevention of disease and other conditions related to inflammation, neurodegeneration, osteoarthritis and apoptosis are also disclosed.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: August 14, 2007
    Assignee: Wyeth
    Inventors: Paul Jeffrey Dollings, Arlene Joan Dietrich, Lisa Marie Havran, Chae-Koo Dan Chong, Donna Mary Huryn, Albert Jean Robichaud, Boyd Lynn Harrison, Wayne Everett Childers, Alexander A. Greenfield, James Jacob Bicksler, Vasilios Marathias
  • Process for making chiral 1,4-disubstituted piperazines
    Patent number: 7256289
    Abstract: A process for a stereoselective preparation of novel chiral nitrogen mustard derivatives useful in synthesizing optically active 1,4-disubstituted piperazines of formula: wherein R, Ar, and Q are defined as set forth herein, and intermediate compounds therefor. The 1,4-disubstituted piperazines act as 5HT1A receptor binding agents useful in the treatment of Central Nervous System (CNS) disorders. The intermediate compounds of Formula II and IV as set forth herein are also included.
    Type: Grant
    Filed: June 7, 2005
    Date of Patent: August 14, 2007
    Assignee: Wyeth
    Inventors: Ivo Ladislav Jirkovsky, Joseph Zeldis, Gregg Brian Feigelson
  • COMPOSITIONS FOR THE DELIVERY OF SUBSTITUTED NAPTHYL INDOLE DERIVATIVES AND METHODS OF THEIR USE
    Publication number: 20070185186
    Abstract: This invention relates to compositions for the delivery of substituted naphthyl indole derivatives as well as to the use of these compositions and methods for treating disease.
    Type: Application
    Filed: January 31, 2007
    Publication date: August 9, 2007
    Applicant: Wyeth
    Inventors: Behnam Abdolalizadeh, T. Armstrong, James Provost, Zerina Shafi, M. Ku
  • Multivalent pneumococcal polysaccharide-protein conjugate composition
    Publication number: 20070184071
    Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection. Methods for making an immunogenic conjugate comprising Streptococcus pneumoniae serotype 19A polysaccharide are also provided in which the serotype 19A polysaccharide is co-lyophilized with a carrier protein and conjugation is carried out in dimethyl sulfoxide (DMSO) via a reductive amination mechanism.
    Type: Application
    Filed: December 22, 2006
    Publication date: August 9, 2007
    Applicant: Wyeth
    Inventors: William Hausdorff, George Siber, Peter Paradiso, A. Prasad
  • CLONING, CHARACTERIZATION, AND APPLICATION OF TNFRSF19 IN NEUROLOGICAL DISORDERS
    Publication number: 20070186296
    Abstract: TNFRSF19 nucleic acids and proteins, TNFRSF19 binding partners and modulators, and methods of using the same.
    Type: Application
    Filed: February 2, 2007
    Publication date: August 9, 2007
    Applicant: Wyeth
    Inventors: Ying Gao, Huai-Ping Ling, Andrew Wood, Kodangattil Sreekumar
  • Multivalent pneumococcal polysaccharide-protein conjugate composition
    Publication number: 20070184072
    Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection. Also described is a method for making an immunogenic conjugate comprising Streptococcus pneumoniae serotype 1 polysaccharide covalently linked to a carrier protein, the method including partial de-O-acetylation of the polysaccharide by mild hydrolysis in an alkaline pH buffer.
    Type: Application
    Filed: December 22, 2006
    Publication date: August 9, 2007
    Applicant: Wyeth
    Inventors: William Hausdorff, George Siber, Peter Paradiso, A. Prasad
  • Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and methods of use thereof
    Patent number: 7253153
    Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof are provided where at least one of R2 or R3 is not hydrogen. The compounds of the present invention are N-methyl-D-aspartate (NMDA) receptor antagonists and are useful in treating a variety of conditions present in a mammal that benefit from inhibiting the NMDA receptor.
    Type: Grant
    Filed: April 7, 2004
    Date of Patent: August 7, 2007
    Assignee: Wyeth
    Inventors: Reinhardt B. Baudy, John A. Butera
  • Indoline derivatives
    Patent number: 7253203
    Abstract: This invention relates to substituted indoline derivative compounds which are antagonists of the progesterone receptor, their preparation and pharmaceutical utility, particularly including contraception and treatment of benign or malignant neoplastic diseases, having the general structure: wherein R1 and R2 may be single substituents or fused to form spirocyclic rings.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: August 7, 2007
    Assignee: Wyeth
    Inventors: Andrew Fensome, Lori L. Miller, John W. Ullrich, Reinhold H. W. Bender, Puwen Zhang, Jay E. Wrobel, Lin Zhi, Todd K. Jones, James P. Edwards, Christopher M. Tegley
  • Processes for the preparation of N-substituted phthalimides
    Patent number: 7253291
    Abstract: The present invention describes a process for preparing N-substituted phthalimides of Formula I which are widely useful as intermediates in the preparation of organic compounds such as pharmaceuticals
    Type: Grant
    Filed: November 16, 2004
    Date of Patent: August 7, 2007
    Assignee: Wyeth
    Inventors: Yanzhong Wu, Panolil Raveendranath